Finally, the effectiveness of epacadostat (IDO inhibitor) and pembrolizumab was recently investigated in a phase III randomized study on 706 patients with unresectable melanoma (ECHO-301/KEYNOTE-252) [282]. Here, IDO1 is linked to melanoma.